Articles Vol. 66 No. 3 26/05/2025

8. VALUE OF RAJAN'S HEART FAILURE (R-HF) SCORE IN PREDICTING SHORT-TERM OUTCOMES IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE

Hoang Huy Truong1,2,3,4, Nguyen Hoang Hai5,6, Nguyen Thi Thu Quyen1,3
1 1. Pham Ngoc Thach University of Medicine, Ho Chi Minh City
2 2. Tam Duc Cardiology Hospital, Ho Chi Minh City
3 1. Trường Đại học Y Khoa Phạm Ngọc Thạch, Thành phố Hồ Chí Minh
4 2. Bệnh viện Tim Tâm Đức, Thành phố Hồ Chí Minh
5 3. Nhan dan Gia Dinh Hospital, Ho Chi Minh City
6 3. Bệnh viện Nhân dân Gia Định, Thành phố Hồ Chí Minh
Corresponding author: truonghh@pnt.edu.vn
DOI: 10.52163/yhc.v66i3.2599
15 Views
9 Downloads
Abstract

Objective: To determine the value of Rajan’s Heart Failure (R-hf) score in predicting 3-month cardiovascular outcomes (CVOs) in patients with acute decompensated heart failure (ADHF).

Methods: A combined prospective and retrospective cohort study was conducted on 233 patients (median age: 67 years; 52.9% female) hospitalized for ADHF. The R-hf score was calculated by multiplying the estimated glomerular filtration rate (eGFR, mL/min/1.73m²), left ventricular ejection fraction (LVEF, %), and hemoglobin level (g/dL), then dividing by NT-proBNP levels (pg/mL). Risk categories were stratified as very low (≥50), low (≥10 to <50), intermediate (≥5 to <10), and high (<5). CVOs included all-cause mortality and rehospitalization due to ADHF within 3 months.

Results: The CVO rate was 22% (n=49), including 3.1% mortality and 18.8% rehospitalization. The median R-hf score was significantly higher in patients without CVOs compared to those with (7.8 vs. 1.7 points, p<0.001). CVO rates increased across risk categories: very low 0%, low 6.6%, intermediate 18%, and high 34.3% (p<0.001). An R-hf score <2.25 demonstrated good predictive ability with an AUC of 0.823 (95% CI: 0.758–0.887), sensitivity of 69.4%, specificity of 85.6%, positive predictive value of 57.6%, and negative predictive value of 90.8%.

Conclusion: The R-hf score had high predictive value for 3-month CVOs in patients with ADHF, providing an effective tool for risk stratification and guiding patient management.

References
[1]
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368 Google Scholar
[2]
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics - 2023 Update: A Report from the American Heart Association. Circulation. 2023;147(8):e93-e621. doi:10.1161/CIR.0000000000001123 Google Scholar
[3]
Văn ĐH, Lưu TH, Lương MT, Nguyễn ĐH, Vũ KT. Nghiên cứu một số yếu tố tiên lượng tử vong ngắn hạn ở bệnh nhân suy tim cấp tại Bệnh viện Đa khoa Hùng Vương. Tạp chí tim mạch học Việt Nam. 2019;88:74-82. Google Scholar
[4]
Rajan R, Jarallah M Al, Al-Zakwani I, et al. Development and Validation of R-hf Risk Score in Acute Heart Failure Patients in the Middle East. Oman Med J. 2023;38(4):e529. doi:10.5001/omj.2023.89 Google Scholar
[5]
He W, Jia J, Chen J, et al. Comparison of prognostic value of red cell distribution width and NT-proBNP for short-term clinical outcomes in acute heart failure patients. Int Heart J. 2014;55(1):58-64. http://www.ncbi.nlm.nih.gov/pubmed/24463920. Google Scholar
[6]
Turcato G, Cervellin G, Bonora A, et al. Red blood cell distribution width improves reclassification of patients admitted to the emergency department with acute decompensated heart failure. J Med Biochem. 2018;37(3):299-306. doi:10.1515/jomb-2017-0054 Google Scholar
[7]
Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938-1952. Google Scholar
[8]
Lee DS, Straus SE, Farkouh ME, et al. Trial of an Intervention to Improve Acute Heart Failure Outcomes. N Engl J Med. 2023;388(1):22-32. doi:10.1056/nejmoa2211680 Google Scholar
[9]
Rajan R, Soman SO, Al Jarallah M, et al. Validation of R-hf risk score for risk stratification in ischemic heart failure patients: A prospective cohort study. Ann Med Surg. 2022;80:104333. doi:10.1016/j.amsu.2022.104333 Google Scholar
[10]
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Google Scholar